Symbols

GH

Guardant Health·NASDAQ

--(--)

GH fundamentals

GH Q4 2025 Earnings

Guardant Health (GH) released its earnings on Feb 19, 2026: revenue was 281.27M (YoY +39.37%), beat estimates; EPS was -1 (YoY -11.11%), missed estimates.

Revenue / YoY

281.27M

+39.37%

EPS / YoY

-1

-11.11%

Report date

Feb 19, 2026

GH Earnings Call Summary for Q4,2025

Revenue Growth: 2025 total revenue $982 million (+33% YoY), oncology $683.6 million (+26%), screening $79.7 million, biopharma $210.1 million (+18%).
Oncology Momentum: Guardant360 liquid +25% YoY, Reveal fastest-growing product, Guardant360 tissue strengthened post-upgrade.
Shield Success: 38,000 Q4 tests (39% YoY), 93% adherence, MCD expansion to 9 cancers, TRICARE coverage.
Financial Health: 2026 guide $1.25-$1.28 billion revenue, core business free cash flow positive, NovaSeq X to improve margins.
Strategic Moves: MetaSight acquisition, Merck collaboration, Quest/PathGroup partnerships, MCD data collection for FDA approval.

Earnings

EPS

Revenue

Revenue & Expenses

GH has released its 2025 Q4 earnings report, with revenue of 281.27M, reflecting a YoY change of 39.37%, and net profit of -128.49M, showing a YoY change of -15.75%. The Sankey diagram below clearly presents GH's revenue sources and cost distribution.

Key Indicators

Guardant Health (GH) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Guardant Health (GH)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Guardant Health (GH)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Guardant Health (GH)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown